Financials in USD. Standardized financial statements.
A compact view of how BioLineRx Ltd. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.19M | $28.94M | $4.80M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | -95.9% | +502.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $758,973 | $9.26M | $3.69M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $430,387 | $19.68M | $1.11M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | +36.2% | +68.0% | +23.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $10.80M | $40.09M | $50.80M | $29.16M | $24.78M | $22.93M | $28.11M | $25.61M | $25.24M | $16.51M |
| Operating Income? | -$10.37M | -$20.41M | -$49.69M | -$29.16M | -$24.78M | -$22.93M | -$28.11M | -$25.61M | -$25.24M | -$16.51M |
| EBITDA? | -$9.84M | $3.92M | -$57.09M | -$28.50M | -$24.07M | -$27.59M | -$22.65M | -$22.04M | -$24.80M | -$15.34M |
| Income Before Tax | -$2.04M | -$9.22M | -$60.61M | -$24.95M | -$27.05M | -$30.02M | -$25.45M | -$22.96M | -$24.35M | -$15.84M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$1.18M | -$9.22M | -$60.61M | -$24.95M | -$27.05M | -$30.02M | -$25.45M | -$22.96M | -$24.35M | -$15.84M |
| EPS? | $-0.29 | $-0.12 | $-0.94 | $-0.48 | $-0.61 | $-1.80 | $-2.70 | $-3.15 | $-4.05 | $-4.20 |
| Diluted EPS? | $-0.29 | $-0.12 | $-0.94 | $-0.48 | $-0.61 | $-1.80 | $-2.70 | $-3.15 | $-4.05 | $-4.20 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality